A nurse on an oncology unit is preparing to administer doxorubicin to a client who has breast cancer. Prior to beginning the infusion, the nurse verifies the client’s current cumulative lifetime dose of the medication. For which of the following reasons is this verification necessary?
A.
Exceeding the lifetime cumulative dose limit of doxorubicin might cause extravasation.
B.
Exceeding the lifetime cumulative dose limit of doxorubicin might produce red tinged urine and sweat.
C.
An excess amount of doxorubicin can lead to cardiomyopathy.
D.
An excess amount of doxorubicin can lead to myelosuppression.
The correct answer and Explanation is :
The correct answer is C. An excess amount of doxorubicin can lead to cardiomyopathy.
Explanation:
Doxorubicin is an anthracycline chemotherapy drug used in the treatment of various cancers, including breast cancer. While effective, it is known for its potential for serious side effects, particularly with regard to the heart. One of the most significant concerns with doxorubicin is its potential to cause cardiomyopathy, which is a type of heart disease that affects the heart muscle’s ability to pump blood effectively.
Cardiomyopathy and Doxorubicin:
- Dose-Dependent Toxicity:
Doxorubicin is associated with dose-dependent cardiotoxicity. This means that the risk of developing heart problems increases with the cumulative dose of the drug. The risk of cardiomyopathy becomes particularly concerning when the cumulative lifetime dose exceeds recommended limits. The maximum recommended cumulative dose is typically around 450-550 mg/m², depending on the patient’s individual health status and any other risk factors. - Mechanism of Cardiotoxicity:
The cardiotoxic effects of doxorubicin are thought to be due to its interaction with the cardiac muscle cells. Doxorubicin generates free radicals and oxidative stress, which can damage cardiac cells and lead to heart muscle injury and dysfunction. This can manifest as cardiomyopathy, congestive heart failure, or other serious cardiac conditions. - Monitoring and Prevention:
To mitigate the risk of cardiotoxicity, it is crucial for healthcare providers to monitor the total cumulative dose of doxorubicin that a patient receives. This monitoring helps ensure that the patient does not exceed the recommended lifetime dose limits, thus reducing the likelihood of severe cardiotoxic effects. Regular cardiac assessments and alternative therapies may be considered if a patient approaches the cumulative dose limit.
In summary, verifying the client’s cumulative lifetime dose of doxorubicin is essential because exceeding this limit can lead to serious cardiac complications, such as cardiomyopathy, which can have profound impacts on the patient’s overall health and treatment outcomes.